A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms

Author(s): Dorota Darmochwal-Kolarz, Bogdan Kolarz, Michal Korzeniewski, Zaneta Kimber-Trojnar, Jolanta Patro-Malysza, Radzisław Mierzynski, Monika Przegalinska-Kałamucka, Jan Oleszczuk

Journal Name: Current Pharmaceutical Biotechnology

Volume 17 , Issue 7 , 2016

Become EABM
Become Reviewer


Pre-eclampsia appears to be the main cause for the maternal and fetal morbidity and mortality. Pregnant women with pre-eclampsia are more likely to be threatened with conditions which potentially may be lethal, such as: disseminated intravascular coagulation, cerebral hemorrhage, liver and renal failure. Pregnancy complicated with pre-eclampsia is also associated with a greater risk for iatrogenic prematurity, intrauterine growth retardation, premature abruption of placenta, and even intrauterine fetal death. In the majority of cases the reasons for arterial hypertension among pregnant women remain obscure. For the past decades, there were many abortive attempts in the use of some microelements, vitamins or specific diets, such as polyunsaturated fatty acids, for the prophylaxis of pre-eclampsia. Recently, it has been shown that a prevention of pre-eclampsia with the use of a lowmolecular- weight heparins (LMWHs) and acetylsalicylic acid (ASA) could considerably reduce the frequency of preeclampsia. In this review, we present the studies concerning the applications of LMWHs and aspirin in the prophylaxis of pre-eclampsia and some important data about the mechanisms of anti-inflammatory actions of LMWHs and ASA.

Keywords: Acetylsalicylic acid, low-molecular-weight heparins, pre-eclampsia, prevention.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [624 - 628]
Pages: 5
DOI: 10.2174/1389201017666160301103312
Price: $65

Article Metrics

PDF: 43